Recently, it has been demonstrated that cancer cells treated with chemotherapy release IL-1β, triggering the release of integrin-αvβ1 and matrix metalloproteinase 9, causing the activation of TGF-β, which in turn promotes EMT in breast cancer cells [243]. The gene discussed is TGFB1; the disease is breast carcinoma.